Mustang Bio (NASDAQ:MBIO) Announces Quarterly Earnings Results

Mustang Bio (NASDAQ:MBIO) posted its earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, FiscalAI reports.

Mustang Bio Price Performance

Shares of MBIO opened at $0.85 on Friday. The company has a market capitalization of $6.20 million, a PE ratio of -2.74 and a beta of 2.13. Mustang Bio has a one year low of $0.53 and a one year high of $7.00. The company’s fifty day moving average price is $0.95 and its 200 day moving average price is $1.22.

Institutional Investors Weigh In On Mustang Bio

An institutional investor recently raised its position in Mustang Bio stock. Kestra Advisory Services LLC increased its holdings in shares of Mustang Bio, Inc. (NASDAQ:MBIO) by 68.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 111,042 shares of the company’s stock after purchasing an additional 44,934 shares during the period. Kestra Advisory Services LLC owned approximately 1.52% of Mustang Bio worth $109,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.